Urachal carcinoma with liver, lung, and brain metastases: benefit of a new combination chemotherapy (bevacizumab, 5-fluorouracil, irinotecan) – case report

achal carcinoma with liver, lung, and brain metastases: benefit of a new combination chemotherapy (bevacizumab, 5-fluorouracil, irinotecan) – case report Case report (2613) Total Article Views Authors: Dekoninck J, Demetter P, Geurs F, De Loecker R Published Date May 2011 Volume 2011:1 Pages 11 - 15 DOI: http://dx.doi.org/10.2147/COAYA.S18841 J Dekoninck1, P Demetter2, Filip Geurs1, R De Loecker3 1Department of Medical Oncology, Regional Hospital Sint Maria, Halle, Belgium; 2Department of Pathology, Hopital Erasme – Université Libre de Bruxelles (ULB), Anderlecht, Belgium; 3Department of Laboratory, Regional Hospital Sint Maria, Halle, Belgium Abstract: After failure of cisplatin-based chemotherapy for metastatic urachal carcinoma, a 16-year-old patient presents with diffuse liver-, lung-, and brain metastases. The K-ras mutation is present in the liver as well as in the primary resected specimen. The regimen was therefore changed to bevacizumab, 5-fluorouracil, and irinotecan. This led to a partial response which lasted 7 months.